“True Terpenes believes terpenes have a high potential to positively impact the quality of human life,” said Chris Campagna, CEO of True Terpenes.
PORTLAND, Ore. (PRWEB) August 13, 2020
True Terpenes, the leading platform for terpene innovation, research and development, recently announced the creation of its Scientific Advisory Board (SAB) to research the medical potential of terpenes and the potential entourage effect, where the benefits of medical cannabis can be enhanced when combined with terpenes. The board is focused on expanding the recently launched line of effects-based terpenes - Terpology by Dr. Ethan Russo - and identifying natural ways to deliver precise doses of cannabinoids and terpenes to be effectively utilized by the human body.
The SAB will provide True Terpenes with external scientific and medical insights, as well as feedback on product and intellectual property development. It will further work to catalyze a long-standing goal of True Terpenes to address the gaps in the science surrounding the entourage effect and create products to optimize these discoveries.
Two scientific luminaries with impressive careers in cannabis research and small molecule development, Dr. Ethan Russo and Dr. Randall Murphy, are inaugural members of the board.
“It was difficult in past times to identify sources of pure compounds, particularly of botanical origin, let alone meeting scientific safety standards or organic cultural origin. All these issues have changed with the advent of True Terpenes, a company that has been dedicated from its beginning to raising industry standards and applying Good Manufacturing Practice to their entire line of products,” said Dr. Russo.
Dr. Russo is a board-certified neurologist, and a research pioneer in cannabis and psychopharmacology, who helped to extend the entourage effect concept to cannabis itself with its collection of cannabinoids and terpenoids. Dr. Russo was also a Senior Medical Advisor for GW Pharmaceuticals’ research on cannabis therapies including Sativex, a cannabinoid treatment for multiple sclerosis (MS) symptoms and severe neuropathic-related pain, and Epidiolex, the first FDA approved botanically-derived cannabis medication.
Dr. Murphy is a former tenured faculty member at New York University who has worked on clinical trials for pharma companies and launched pharma startups. He designed laboratories and the widely used standards and practices in place in the U.S. National Bureau of Standards and Center for Analytical Chemistry, and the Staff Research Fellow Laboratory of Biophysical Chemistry. His work with the SAB will be primarily directed at leading a similar expansion of laboratory facilities and advising on the product and development of True Terpenes projects.
The True Terpenes SAB and the True Terpenes product development team will utilize the cutting-edge research and the company’s GMP/ISO/FSSC-certified production facilities to unlock the functional benefits of terpenes and cannabinoids.
Terpenes are traditionally associated with flavor and aroma, but the SAB will focus more on the physical effects terpenes can provide, known as the entourage effect. The entourage effect is a theory on how the various compounds in cannabis and our bodies interact synergistically to create a variety of therapeutic effects. Terpenes play a key role in the entourage effect by modulating the impact of cannabinoids, including CBD and THC. The resulting outcome of these compounds working together, rather than alone, leads to a more potent effect with a broader set of potential applications.
“True Terpenes believes terpenes have a high potential to positively impact the quality of human life,” said Chris Campagna, CEO of True Terpenes. “With the help of Dr. Russo and Dr. Murphy, the SAB will help unlock this value with science-driven outcomes, and provide our company with the world-class expertise and guidance needed to expand our research around terpenes, the entourage effect, and cannabis.”
About True Terpenes
True Terpenes, a fully owned subsidiary of True Companies, is the industry-leading producer of effects-based, GMP/ISO/FSSC-certified terpenes and terpenoids blends. Using ultra-refined botanical terpenes and other aromatic compounds, the custom terpene blends are used for beverage, cannabis, cosmetic, food, industrial and pharmaceutical products. The company uses advanced scientific analysis to identify terpenes and other compounds in the cannabis plant for recreation by utilizing other botanicals and hemp-derived ingredients. This allows companies in various industries looking to leverage cannabis flavors and effects with a scalable, standardized, and worldwide legal solution.
Any forward-looking statements included in this document are made as of the date of this document and Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Although management of the Corporation believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct.
Samantha Qualls, Senior Director